The PRICED Act takes aim at Big Pharma’s price gouging by reducing the window drug companies are allowed to retain exclusive marketing rights for biologics, from twelve years to five. The legislation could could save Medicare, and therefore patients, upwards of $7 billion over ten years.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.